Isomorphic Labs Starts Human Trials for AI Drugs

Isomorphic Labs, a biotechnology company and spinoff of Google DeepMind, announced the start of human clinical trials for its first AI-designed molecules ^[1]. This milestone signals a transition from mapping biological structures to actively designing and testing new therapeutics ^[1]. The initial focus for these molecules includes treatments for diseases such as cancer ^[1].

These trials represent a critical moment for the industry, as results could define pharmaceutical development for the next decade ^[2]. Experts note that moving from digital mapping to human testing highlights a growing integration of artificial intelligence and human physiology ^[3]. Isomorphic Labs aims to move beyond previous mapping successes to create tangible medical solutions ^[1][2].